Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis
- PMID: 40857020
- PMCID: PMC12428506
- DOI: 10.1002/mus.70011
Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis
Abstract
Introduction/aims: Expanded access protocols (EAPs) allow individuals ineligible for clinical trials to receive investigational products. EAP data can be collected in parallel to randomized clinical trials (RCTs) and serve as a source of evidence in clinical practice. Here, we present the results of a National Institutes of Health (NIH)-funded EAP for amyotrophic lateral sclerosis (ALS).
Methods: Participants received trehalose, a drug studied in a parallel RCT, for up to 24 weeks; clinical and biomarker data were collected throughout the study.
Results: Seventy participants were enrolled at 20 study centers across the United States. Treatment with trehalose did not affect the levels of neurofilament light chain [estimated flat slope per month was -0.005, SE = 0.0078; 95% CI (-0.021, 0.011)] or disease progression [estimated least square mean change of the ALS Functional Rating Scale-Revised total score and slow vital capacity (percent predicted) from baseline to Week 24 were -5.6 (0.67); 95% CI (-7.0, -4.3) and -4.53 (4.308); 95% CI (-13.55, 4.48)], respectively. No unexpected treatment-related risks were identified. Serious adverse events were deemed not related to trehalose (20 occurrences in 13 [18.6%] participants with eight deaths).
Discussion: This EAP establishes a framework for implementing multi-center EAPs that complement data collected from RCTs. Additional NIH-funded EAPs are currently underway. Data and additional serum samples collected in this study are available to the research community for further study.
Trial registration: ClinicalTrials.gov: NCT05597436.
Keywords: amyotrophic lateral sclerosis; expanded access; investigational product; motor neuron disease; trehalose.
© 2025 The Author(s). Muscle & Nerve published by Wiley Periodicals LLC.
Conflict of interest statement
Disclosure of Conflicts of Interest
The remaining authors declare no potential conflicts of interest.
References
-
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585–91. - PubMed
-
- Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2022;387(12):1099–110. - PubMed
-
- Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, et al. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2020;61(8):1965–73. - PubMed
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous